## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
hours per response	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person *- POWELL MICHAEL				2. Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director				
(Last) (First) (Middle) C/O SOFINNOVE VENTURE PARTNERS INC, 140 GEARY BLVD 10TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 05/13/2008												
(Street) SAN FRANCISCO, CA 94108			4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)			Ta	able l	I - Non-De	rivative	Securitie	es Acquire	ed, Disposed	of, or Bene	ficially Own	d	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea		Date, if (	(Instr. 8)		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		of (D) Ov Tr	Transaction(s) (Instr. 3 and 4)		d (	Ownership Form: Direct (D) or Indirect I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Co	de V	Amount	(D)	Price				Instr. 4)	
			Table II -					displa uired, Dis	posed of	, or Bene	eficially O	B control r	number.			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A or Disposed of (D) (Instr. 3, 4, and 5)		Expiration (Month/D	Exercisable and on Date Day/Year)		7. Title a of Under Securitie (Instr. 3 a	s		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownersh Form of Derivativ Security: Direct (D or Indirects)	Beneficia Ownersh (Instr. 4)
				Code	v	(A)	(D)	Date Exercisab		ration	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (Right to Buy)	\$ 0.36	05/13/2008		A		15,000		(2)	05/1	2/2018	Commo	115.000	\$ 0	15,000	D	

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
POWELL MICHAEL C/O SOFINNOVE VENTURE PARTNERS INC 140 GEARY BLVD 10TH FLOOR SAN FRANCISCO, CA 94108	X					

#### **Signatures**

Michael Powell by Joel Fernandes, Attorney-in-Fact	05/14/2008
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The stock option was granted pursuant to the Threshold Pharmaceuticals, Inc. 2004 Amended and Restated Equity Incentive Plan.
- (2) The option shall vest and become exercisable at the rate of 1/12 of the shares on each monthly anniversary following the grant date of May 13, 2008, with the last installment to vest on the date of the Company's annual stockholder meeting for the year following the date the option was granted.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.